Patents by Inventor Bilal Piperdi

Bilal Piperdi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS
    Publication number: 20230050449
    Abstract: Provided herein are methods of treating cancer (e.g., NSCLC), which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) an ILT4 antagonist; and (c) one or more chemotherapeutic agents. Also provided are pharmaceutical compositions and kits containing such agents for the treatment of cancer.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Philip E. Brandish, Rachel A. Altura, Bilal Piperdi
  • Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor
    Publication number: 20060084691
    Abstract: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and bortezomib combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and bortezomib combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlitinib HCl (also known as Tarceva™).
    Type: Application
    Filed: October 17, 2005
    Publication date: April 20, 2006
    Inventor: Bilal Piperdi